化合物 DC260126|T7127|TargetMol

價(jià)格	￥415	￥581	￥1255
包裝	5mg	10mg	25mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 DC260126	英文名稱:DC260126
CAS:346692-04-4	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.77%	產(chǎn)品類別: 抑制劑
貨號(hào): T7127

Product Introduction

Bioactivity

名稱	DC260126
描述	DC260126 is a small-molecule antagonist of FFA1 (GPR40)
動(dòng)物實(shí)驗(yàn)	To investigate the dose-dependent effect of DC260126, nine-week-old db/db male mice were divided into four groups (n = 6/group). Mice were give vehicle (5% DMSO in PBS) or DC260126 (3, 10, 30 mg/kg) once daily by tail vein injection for 5 days. At day 5, each group of mice were fasted for 6 h and blood samples were collected from orbital venous plexus and centrifuged for serum separation. Then the concentration of serum insulin level was measured by ELISA kit following its protocol. For long term experiments, six-week-old obese db/db male mice were divided into two groups (n = 8/group) and given vehicle (5% DMSO in PBS) or DC260126 (10 mg/kg) once daily by tail vein injection for 24 days, respectively. Meanwhile, their lean littermates were treated with vehicle in an identical manner as normal control. Body weight and food intake were recorded regularly. After 6 h fasting, blood glucose concentrations were monitored by tail vein blood using a glucometer every week. At the end of the experiment, mice were fasted for 12 h to perform oral glucose tolerance test (OGTT, day 21) and for 6 h to generate insulin tolerance test (ITT, day 23) as described with slight modification indicated . Meanwhile, the insulin release during OGTT was also measured, blood sample was obtained from tail veins and serum insulin concentration was determined by ELISA kit (Alpco, USA). At the end of experiment (day 24), mice were fasted for 6 h, and blood samples were collected from orbital venous plexus and centrifuged for serum separation. Then the animals were killed by CO2 inhalation, the pancreas tissue were removed and kept in 4% paraformaldehyde[1].
體內(nèi)活性	DC260126, a small molecule antagonist of GPR40, on β-cell function following administration of 10 mg/kg dose of DC260126 to obese diabetic db/db mice. Oral glucose tolerance test, glucose stimulated insulin secretion and insulin tolerance test were used to investigate the pharmacological effects of DC260126 on db/db mice after 21-days treatment. Immunohistochemistry and serum biochemical analysis were also performed. Although no significant change of blood glucose levels was found in DC260126-treated mice, DC260126 significantly inhibited glucose stimulated insulin secretion, reduced blood insulin level and improved insulin sensitivity after 3 weeks administration in db/db mice. Moreover, DC260126 reduced the proinsulin/insulin ratio and the apoptotic rate of pancreatic β-cells remarkably in DC260126-treated db/db mice compared to vehicle-treated mice (p<0.05, n = 8). Suggest that although DC260126 could not provide benefit for improving hyperglycemia, it could protect against pancreatic β-cells dysfunction through reducing overload of β-cells, and it increases insulin sensitivity possibly via alleviation of hyperinsulinemia in db/db mice[1].
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 100 mg/mL (325.33 mM)
關(guān)鍵字	stress \| secretion \| phosphorylation \| insulin \| Inhibitor \| inhibit \| Free Fatty Acid Receptor \| FFAR \| elevation \| DC-260126 \| DC260126 \| DC 260126 \| Ca2+ \| Apoptosis
相關(guān)產(chǎn)品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相關(guān)庫(kù)	抑制劑庫(kù) \| 經(jīng)典已知活性庫(kù) \| 抗癌化合物庫(kù) \| 已知活性化合物庫(kù) \| 含氟化合物庫(kù) \| 細(xì)胞凋亡化合物庫(kù) \| 內(nèi)分泌激素分子庫(kù) \| NO PAINS 化合物庫(kù) \| GPCR靶點(diǎn)分子庫(kù) \| 膜蛋白靶向化合物庫(kù) \| 內(nèi)質(zhì)網(wǎng)應(yīng)激化合物庫(kù)

關(guān)鍵字： DC260126|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.265100萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊(cè)資本：566.265100萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 3’-O-Levulinyl-2’-deoxyadenosine|TNU1126|TargetMol

詢價(jià)

化合物 VZ185|T17249|TargetMol

￥5140

化合物 STM3006|T83630|TargetMol

￥867